ClinicalTrials.gg
CompletedNCT00647270Updated Apr 11, 2011Results posted

Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing

A Phase 3 interventional study of adalimumab and Placebo in Rheumatoid Arthritis, sponsored by Abbott. Completed at 86 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-11.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.

Enrollment
23rd of 87
420 · median 160
Started
2007
with 6 others
Phase 3
36 of 87
1 open now
Registered
22nd of 87
by date
Lead sponsor
22 of 87
Abbott

Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 23rd largest by enrollment, is one of 7 that started in 2007, is one of 36 in phase 3, and was the 22nd registered.

Arthritis, Rheumatoid

3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing adalimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

To demonstrate the efficacy of 80 mg adalimumab monthly dosing compared with placebo and demonstrate the non-inferiority of monthly dosing of 80 mg adalimumab compared with dosing of 40 mg adalimumab every other week.

Read the detailed description

The objective of this study is to demonstrate the efficacy of 80 mg adalimumab monthly dosing compared with placebo as measured by ACR20 response criteria following 12 weeks of therapy. The study is also designed to demonstrate the non-inferiority of monthly dosing of 80 mg adalimumab compared with dosing of 40 mg adalimumab eow as measured by ACR20 response criteria at Week 12.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject > 18 years of age
  • Subject has a diagnosis of RA as defined by the 1987-revised ACR-classification criteria and has a disease duration for a minimum of three months
  • Subject must meet the following two criteria: a) At least 6 swollen joints out of 66 assessed, or b) At least 6 tender joints out of 68 assessed
  • If a subject is on MTX, the doses must be stable for at least 4 weeks prior to Screening blood draw and follow standard recommendations for MTX treatment
  • Subject is judged to be in generally good health as determined by the principal investigator

Exclusion criteria

Exclusion Criteria:

  • Subject has previous exposure to any systemic anti-TNF therapy (eg, infliximab, etanercept, certolizumab pegol or golimumab) including adalimumab
  • Subject has a history of acute inflammatory joint disease of different origin other than RA
  • Subject has been treated with any biologic agents
  • Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study
  • Female subject who is pregnant or breast-feeding or considering becoming pregnant
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
420 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo 12 weeks, 40mg adalimumab remaining 12 weeks

    Drug: Placebo

  • Active comparator
    40 mg

    40 mg every other week

    Drug: adalimumab

  • Active comparator
    80 mg

    80 mg monthly

    Drug: adalimumab

Interventions

  • Pre-filled syringe. See arm for more detail

    Also known as: ABT-D2E7, Humira

  • DrugPlacebo

    Pre-filled syringe. See arm for more detail

  • Pre-filled syringe. See arm for more detail

    Also known as: ABT-D2E7, Humira

06

What researchers measure

Primary outcomes

  1. The Number of Responders According to the American College of Rheumatology (ACR) 20 Response Criteria at Week 12 Involving the Comparison of Adalimumab 80 mg Monthly Dose Versus Placebo and Adalimumab 40 mg Every Other Week (Eow)

    Comparison of adalimumab 80 mg monthly dose versus placebo and adalimumab 40 mg eow in the number of responders with ACR criteria improvement consisting of 20%, (ACR20) reduction in tender or swollen joint counts (TJC or SJC, respectively) and 20% improvement in 3 of the following 5 criteria: \[1\] physician's global assessment of disease activity (PGA), \[2\] subject's assessment of disease activity, \[3\] subject's assessment of pain, \[4\] subject's assessment of physical disability via a health assessment questionnaire disability index(HAQ-DI), and \[5\] C-reactive protein (CRP) at each visit

    Time frame: Week 12

Secondary outcomes

  1. Within Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Observed)

    The HAQ-DI is a self-reported subject measure of physical function calculated as the mean of 8 category scores: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Each category score is calculated as the maximum of the scores for the questions within the category. The HAQ-DI is expressed on a scale of 0 (without any difficulty) to 3 (unable to do) representing an average score across the category. Scores for at least 6 categories are needed to compute the HAQ score. Changes to lower scores indicate improvement in physical function.

    Time frame: Baseline and Week 12

  2. Within Group Mean Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Last Observation Carried Forward [LOCF])

    The HAQ-DI is a self-reported subject measure of physical function calculated as the mean of 8 category scores: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Each category score is calculated as the maximum of the scores for the questions within the category. The HAQ-DI is expressed on a scale of 0 (without any difficulty) to 3 (unable to do) representing an average score across the category. Scores for at least 6 categories are needed to compute the HAQ score. Changes to lower scores indicate improvement in physical function.

    Time frame: Baseline and Week 12

  3. Between Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Observed)

    The HAQ-DI is a self-reported subject measure of physical function calculated as the mean of 8 category scores: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Each category score is calculated as the maximum of the scores for the questions within the category. The HAQ-DI is expressed on a scale of 0 (without any difficulty) to 3 (unable to do) representing an average score across the category. Scores for at least 6 categories are needed to compute the HAQ score. Changes to lower scores indicate improvement in physical function.

    Time frame: Baseline and Week 12

  4. Between Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Last Observation Carried Forward [LOCF])

    The HAQ-DI is a self-reported subject measure of physical function calculated as the mean of 8 category scores: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Each category score is calculated as the maximum of the scores for the questions within the category. The HAQ-DI is expressed on a scale of 0 (without any difficulty) to 3 (unable to do) representing an average score across the category. Scores for at least 6 categories are needed to compute the HAQ score. Changes to lower scores indicate improvement in physical function.

    Time frame: Baseline and Week 12

07

Results

Posted May 10, 2010
Limitations and caveats
Abbott identified Investigator non-compliance with the protocol requirements at one site and made the decision to exclude the data from this site from all efficacy analyses. Sample size was too small to demonstrate superiority and non-inferiority.

Participant flow

The study was conducted at 72 sites in the United States, Canada, Puerto Rico, Germany, the United Kingdom, and Australia. Subjects received over the course of 24 weeks either 80 mg adalimumab monthly, 40 mg adalimumab every other week (eow), or placebo (12 weeks) followed by 40 mg adalimumab eow (12 weeks).

Period 1, Placebo-control (12 Weeks)
Participant flow — Period 1, Placebo-control (12 Weeks)
MilestonePlaceboAdalimumab 40 mg EowAdalimumab 80 mg Monthly
Started56159205
Completed48146182
Not completed81323
Withdrew: Adverse event277
Withdrew: Lost to follow-up011
Withdrew: Withdrawal by subject217
Withdrew: Other448
Period 2, Placebo Switched to Adalimumab
Participant flow — Period 2, Placebo Switched to Adalimumab
MilestonePlaceboAdalimumab 40 mg EowAdalimumab 80 mg Monthly
Started48146182
Completed45137175
Not completed397
Withdrew: Adverse event133
Withdrew: Withdrawal by subject004
Withdrew: Other260

Outcome measures

PrimaryThe Number of Responders According to the American College of Rheumatology (ACR) 20 Response Criteria at Week 12 Involving the Comparison of Adalimumab 80 mg Monthly Dose Versus Placebo and Adalimumab 40 mg Every Other Week (Eow)

Comparison of adalimumab 80 mg monthly dose versus placebo and adalimumab 40 mg eow in the number of responders with ACR criteria improvement consisting of 20%, (ACR20) reduction in tender or swollen joint counts (TJC or SJC, respectively) and 20% improvement in 3 of the following 5 criteria: \[1\] physician's global assessment of disease activity (PGA), \[2\] subject's assessment of disease activity, \[3\] subject's assessment of pain, \[4\] subject's assessment of physical disability via a health assessment questionnaire disability index(HAQ-DI), and \[5\] C-reactive protein (CRP) at each visit

Time frame:
Week 12
Reported as:
Number · participants
The Number of Responders According to the American College of Rheumatology (ACR) 20 Response Criteria at Week 12 Involving the Comparison of Adalimumab 80 mg Monthly Dose Versus Placebo and Adalimumab 40 mg Every Other Week (Eow)
participantsPlaceboAdalimumab 40 mg EowAdalimumab 80 mg Monthly
Responders198097
Nonresponders3779108
Statistical analysis
  • Placebo vs Adalimumab 80 mg Monthly · Chi-squared · p = 0.074 · Mean difference (final values): -3.0 · 95% CI -13.3 to 7.4Treatment difference between adalimumab 80 mg monthly and placebo divided by the difference between adalimumab 40 mg eow and placebo.
  • Adalimumab 40 mg Eow vs Adalimumab 80 mg Monthly · Chi-squared · p = 0.74 (Non - inferiority of adalimumab 80 mg monthly compared with 40 mg eow could not be tested because the null hypothesis of the first comparison was not rejected.)
SecondaryWithin Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Observed)

The HAQ-DI is a self-reported subject measure of physical function calculated as the mean of 8 category scores: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Each category score is calculated as the maximum of the scores for the questions within the category. The HAQ-DI is expressed on a scale of 0 (without any difficulty) to 3 (unable to do) representing an average score across the category. Scores for at least 6 categories are needed to compute the HAQ score. Changes to lower scores indicate improvement in physical function.

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a score
Within Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Observed)
units on a scorePlaceboAdalimumab 40 mg EowAdalimumab 80 mg Monthly
Within Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Observed)-0.11 ± 0.488-0.41 ± 0.508-0.39 ± 0.536
Statistical analysis
  • Placebo vs Adalimumab 80 mg Monthly · ANCOVA · p = 0.002
SecondaryWithin Group Mean Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Last Observation Carried Forward [LOCF])

The HAQ-DI is a self-reported subject measure of physical function calculated as the mean of 8 category scores: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Each category score is calculated as the maximum of the scores for the questions within the category. The HAQ-DI is expressed on a scale of 0 (without any difficulty) to 3 (unable to do) representing an average score across the category. Scores for at least 6 categories are needed to compute the HAQ score. Changes to lower scores indicate improvement in physical function.

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a score
Within Group Mean Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Last Observation Carried Forward [LOCF])
units on a scorePlaceboAdalimumab 40 mg EowAdalimumab 80 mg Monthly
Within Group Mean Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Last Observation Carried Forward [LOCF])-0.12 ± 0.484-0.40 ± 0.507-0.37 ± 0.537
Statistical analysis
  • Placebo vs Adalimumab 80 mg Monthly · ANCOVA · p = 0.005
  • Placebo vs Adalimumab 40 mg Eow · ANCOVA · p = 0.002
SecondaryBetween Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Observed)

The HAQ-DI is a self-reported subject measure of physical function calculated as the mean of 8 category scores: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Each category score is calculated as the maximum of the scores for the questions within the category. The HAQ-DI is expressed on a scale of 0 (without any difficulty) to 3 (unable to do) representing an average score across the category. Scores for at least 6 categories are needed to compute the HAQ score. Changes to lower scores indicate improvement in physical function.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a score
Between Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Observed)
units on a scorePlaceboAdalimumab 40 mg EowAdalimumab 80 mg Monthly
Between Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Observed)0 ± 0-0.26 ± 0.081-0.24 ± 0.079
Statistical analysis
  • Placebo vs Adalimumab 40 mg Eow vs Adalimumab 80 mg Monthly · ANCOVA · p = 0.002 (The ANCOVA Model was adjusted for the Baseline Measure.)
SecondaryBetween Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Last Observation Carried Forward [LOCF])

The HAQ-DI is a self-reported subject measure of physical function calculated as the mean of 8 category scores: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Each category score is calculated as the maximum of the scores for the questions within the category. The HAQ-DI is expressed on a scale of 0 (without any difficulty) to 3 (unable to do) representing an average score across the category. Scores for at least 6 categories are needed to compute the HAQ score. Changes to lower scores indicate improvement in physical function.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a score
Between Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Last Observation Carried Forward [LOCF])
units on a scorePlaceboAdalimumab 40 mg EowAdalimumab 80 mg Monthly
Between Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Last Observation Carried Forward [LOCF])0 ± 0-0.24 ± 0.077-0.21 ± 0.075
Statistical analysis
  • Placebo vs Adalimumab 80 mg Monthly · ANCOVA · p = 0.005 (The ANCOVA Model was adjusted for Baseline Measure.)The ANCOVA Model was adjusted for Baseline Measure.

Adverse events

Collected over 24 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Every Other Week (Eow)-Period 1—5/57 (8.8%)13/57 (22.8%)
Adalimumab 40 mg Eow -Period 1—8/164 (4.9%)29/164 (17.7%)
Adalimumab 80 mg Monthly-Period 1—4/211 (1.9%)38/211 (18%)
Placebo/Adalimumab 40 mg Eow-Period 2—1/49 (2%)6/49 (12.2%)
Adalimumab 40 mg Eow-Period 2—5/151 (3.3%)14/151 (9.3%)
Adalimumab 80 mg Monthly - Period 2—12/188 (6.4%)11/188 (5.9%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventPlacebo Every Other Week (Eow)-Period 1Adalimumab 40 mg Eow -Period 1Adalimumab 80 mg Monthly-Period 1Placebo/Adalimumab 40 mg Eow-Period 2Adalimumab 40 mg Eow-Period 2Adalimumab 80 mg Monthly - Period 2
PneumoniaInfections and infestations0/574/1640/2110/491/1510/188
DeathGeneral disorders0/570/1640/2111/490/1510/188
Drug toxicityInjury, poisoning and procedural complications1/570/1640/2110/490/1510/188
Femur fractureInjury, poisoning and procedural complications1/570/1640/2110/490/1510/188
Patella fractureInjury, poisoning and procedural complications1/570/1640/2110/490/1510/188
ArteriosclerosisVascular disorders1/570/1640/2110/490/1510/188
HaematomaVascular disorders1/570/1640/2110/490/1510/188
Urinary tract infectionInfections and infestations0/572/1640/2110/490/1511/188
CellulitisInfections and infestations0/570/1642/2110/491/1510/188
Ankle fractureInjury, poisoning and procedural complications0/570/1640/2110/491/1510/188
Most frequent other events
Most frequent other events
EventPlacebo Every Other Week (Eow)-Period 1Adalimumab 40 mg Eow -Period 1Adalimumab 80 mg Monthly-Period 1Placebo/Adalimumab 40 mg Eow-Period 2Adalimumab 40 mg Eow-Period 2Adalimumab 80 mg Monthly - Period 2
diarrhoeaGastrointestinal disorders4/572/1644/2110/490/1510/188
upper respiratory tract infectionInfections and infestations4/575/16411/2113/494/1516/188
nasopharyngitisInfections and infestations3/578/1642/2113/4910/1515/188
nauseaGastrointestinal disorders3/579/16413/2110/490/1510/188
dizzinessNervous system disorders3/574/1645/2110/490/1510/188
headacheNervous system disorders3/578/16410/2110/490/1510/188
coughRespiratory, thoracic and mediastinal disorders3/571/1641/2110/490/1510/188

Baseline characteristics

Age, Customized
Age, Customized(participants)PlaceboAdalimumab 40 mg EowAdalimumab 80 mg MonthlyTotal
< 65 years43113148304
>= 65 years134657116
Age Continuous
Age Continuous(years)PlaceboAdalimumab 40 mg EowAdalimumab 80 mg MonthlyTotal
Mean54.4 ± 12.4657.2 ± 12.7956.3 ± 12.4356.4 ± 12.58
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAdalimumab 40 mg EowAdalimumab 80 mg MonthlyTotal
Female43122149314
Male133756106
08

Study locations

86 sites
  • Huntsville, Alabama 35801, United States
  • Tuscaloosa, Alabama 35406, United States
  • Paradise Valley, Arizona 85253, United States
  • Hemet, California 92543, United States
  • Long Beach, California 90806, United States
  • Santa Monica, California 90404, United States
  • Torrance, California 90505, United States
  • Victorville, California 92395, United States
  • West Hills, California 91307, United States
  • Wheatridge, Colorado 80033, United States
  • Aventura, Florida 33180, United States
  • Orange Park, Florida 32073, United States
  • Palm Harbor, Florida 34684, United States
  • Sarasota, Florida 34239, United States
  • Tampa, Florida 33614, United States
  • Vero Beach, Florida 32960, United States
  • Atlanta, Georgia 30342, United States
  • Chicago, Illinois 60612, United States
  • Moline, Illinois 61201, United States
  • Springfield, Illinois 62704, United States
  • Wichita, Kansas 67203, United States
  • Lexington, Kentucky 40515, United States
  • Covington, Louisiana 70433, United States
  • Brighton, Michigan 48116, United States
  • Passaic, New Jersey 07055, United States
  • Bronx, New York 10461, United States
  • Smithtown, New York 11787, United States
  • Ashville, North Carolina 28801, United States
  • Charlotte, North Carolina 28209, United States
  • Hickory, North Carolina 28601, United States
  • Monroe, North Carolina 28112, United States
  • Oklahoma City, Oklahoma 73112, United States
  • Bend, Oregon 97701, United States
  • Bethlehem, Pennsylvania 18015, United States
  • Duncansville, Pennsylvania 16635, United States
  • Philadelphia, Pennsylvania 19152, United States
  • West Reading, Pennsylvania 19611, United States
  • Charleston, South Carolina 29406, United States
  • Greenville, South Carolina 29601, United States
  • Jackson, Tennessee 38305, United States
  • Nashville, Tennessee 37205, United States
  • Dallas, Texas 75235, United States
  • Houston, Texas 77034, United States
  • Houston, Texas 77074, United States
  • San Antonio, Texas 78217, United States
  • Ogden, Utah 84405, United States
  • Olympia, Washington 98502, United States
  • Glendale, Wisconsin 53217, United States
  • Brisbane, Queensland 4102, Australia
  • Cairns, Queensland 4870, Australia
  • Winnipeg, Manitoba R3A 1M3, Canada
  • Winnipeg, Manitoba R3N 0K6, Canada
  • Fredericton, New Brunswick E3B 6H5, Canada
  • St. John's, Newfoundland and Labrador A1B 3E1, Canada
  • Lunenburg, Nova Scotia B0J 2C0, Canada
  • Burlington, Ontario L7M 4Y1, Canada
  • Hamilton, Ontario L8N 1Y2, Canada
  • Hamilton, Ontario L8N 2B6, Canada
  • Kitchener, Ontario N2M 5N6, Canada
  • Newmarket, Ontario L3Y 3R7, Canada
  • Ottawa, Ontario K1H 1A2, Canada
  • Sarnia, Ontario N7T 5W6, Canada
  • St. Catherines, Ontario L2N 4H4, Canada
  • Windsor, Ontario N8X 5A6, Canada
  • Montreal, Quebec H2L 1S6, Canada
  • Sainte-Foy, Quebec G1W 4R4, Canada
  • St. Eustache, Quebec J7P 4J2, Canada
  • Quebec, G1V 3M7, Canada
  • Bad Nauheim, D-61231, Germany
  • Berlin-Buch, D-13125, Germany
  • Berlin, D-14109, Germany
  • Frankfurt, 60596, Germany
  • Freiburg, D-79106, Germany
  • Muenchen, 80639, Germany
  • Wuerzburg, D-97070, Germany
  • Zerbst, D-39261, Germany
  • Caguas, 00725, Puerto Rico
  • Ponce, 00716, Puerto Rico
  • Wirral, Cheshire CH49 5PE, United Kingdom
  • Liverpool, Merseyside L9 7AL, United Kingdom
  • Oxford, Oxfordshire OX3 7LD, United Kingdom
  • Bath, Somerset BA1 1RL, United Kingdom
  • Cannock, Staffordshire WS11 5XY, United Kingdom
  • Newcastle upon Tyne, Tyne and Wear NE7 7 DN, United Kingdom
  • Leeds, Yorkshire LS7 4SA, United Kingdom
  • Huddersfield, York HD3 3EA, United Kingdom
09

References and documents

Publications

  • Burmester GR, Landewe R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017 Feb;76(2):414-417. doi: 10.1136/annrheumdis-2016-209322. Epub 2016 Jun 23. PubMed 27338778 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2008
First posted
Mar 31, 2008
Start
Dec 2007
Primary completionActual
Apr 2009
CompletionActual
Apr 2009
Results first posted
May 10, 2010
Last update
Apr 11, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00647270
Lead sponsor
Abbott
First posted
Mar 31, 2008
Start date
Dec 2007
Primary completion
Apr 2009
Completion
Apr 2009
Results posted
May 10, 2010
Last update
Apr 11, 2011

Study contacts

Laura Redden, MD
study director · Abbott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion